Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma’s ambitious restructuring.
<a href="https://www.fiercebiotech.com/biotech/novo-drops-oncology-ambitions-early-stage-mash-prospects-ongoing-rd-shake" hreflang="en">Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&D shake-up</a>
FierceBiotech | | James Waldron
Topics: oncology